Four new treatments produce 83-"100"% remissions of resistant ovarian cancer
October 26, 2013
October 24-27
COGI; Vienna, Austria: A treatment strategy (* cited below) has been modified for use against both resistant ovarian cancer and resistant endometrial cancer. A combination of interactive partner drugs can reverse a tumor's resistance to many drugs. For 30 patients, a new drug pair, Avastin and cyclophosphamide (ACy), known to inhibit growth factors, produced 83-"100"% rates of partial and complete remissions, when added to a combination of drugs that the patient had already "failed". When used again for the same patients, with what are widely recognized as the most difficult classes of resistant tumors, the combination of failed drugs, gemcitabine, fluorouracil, Irinotecan, carboplatin and Docetaxel - taxotere,(GFLIC D), in lower safer, 1/2-1/4, dosages, improved the rates-chances of "high value" response in a statistically significant fashion in every tested subgroup of patients(p= 0.03-0.008) Responses produce complete remissions and other opportunities for potentially curative treatment; responses allow ideal surgery and intraperitoneal belly bath therapy, and immunotherapy. Responses increased relapse free survival, two fold or more, for heavily treated and sick patients and very frequently correct life threatening catastrophic complications. There are no standard treatments, for patients with these stages and complications of resistant tumor, with similar objectives. although such treatments are urgently needed for 200-600 (additional) patients per day in the USA and G8-EU countries. This project is an ongoing prospective attempt to push the therapeutic envelope, expand the number of patients eligible for high value treatments. ACy GFLIC D can largely solve the current common failure to provide ovarian cancer patients with life saving surgery and belly bath- intraperitoneal therapy; the important impact of this major systemic health care failure was highlighted at the 2013 Los Angeles Women's Health Conference and in The New York Times columns and Editorial pages.
The presenter,HW Bruckner MD, is a former professor, author of 150 plus publications and 200 more abstracts applicable to the interaction, safety, and new uses of anti cancer drugs. He was the first to describe the use of platinum for ovarian cancer (ASCO) and high dose platinum for resistant ovarian cancer
Novel applications and results of treatment, include : 1) 5 out of 5 times, complete responses followed "early failure" of first (standard) treatments to produce ideal remission; these primary platinum resistant tumors convenionally carry a poor prognosis; 2) 7 out of 7 times, 2-6 cm size tumors were reduced in size enough to make patients eligible for surgery and belly bath,"after five standard treatments had failed" ; 3) 7 out of 8 times, partially bed bound patients, also resistant to five prior treatments, were rescued from a "life threatening crises",( currently these patients too often are not offered any treatment) The implication is that palliative treatment of stable disease, tumors neither increasing nor decreasing in size, can be replaced with serial treatments in order to reduce the size of the tumors and allow potentially curative further treatments.
Experience with GFLIC like combinations introduces strategies which can safely double the value and applications of targeted biologic therapy and has had analogous broad applications (*cited below)to other target drugs and diseases when coupled to the above drug combinations and positioning, timing of treatment intervention, strategies..
* Bruckner and others: ASCO 01 pancreatic cancer; ASCO 06 gastric cancer; ASCO 08,12, pancreatic cancer and ASCO 12 cholangio,bile duct cancer describe development of these multimechanism five way biochemical modulating and five way metronomic regimens.
Bruckner cautions that this should not be used as a substitute for primary standard "potentially curative" treatments nor should it be used without an eligibility and safety evaluation perfomed by an expert familiar with the patient, the disease and the drugs
Contact information [email protected]
|
|
